Compare IND. SWIFT with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IND. SWIFT vs PARNAX LAB - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IND. SWIFT PARNAX LAB IND. SWIFT/
PARNAX LAB
 
P/E (TTM) x -2.9 79.0 - View Chart
P/BV x - 2.1 - View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 IND. SWIFT   PARNAX LAB
EQUITY SHARE DATA
    IND. SWIFT
Mar-21
PARNAX LAB
Mar-21
IND. SWIFT/
PARNAX LAB
5-Yr Chart
Click to enlarge
High Rs539 12.7%   
Low Rs212 16.0%   
Sales per share (Unadj.) Rs65.7106.0 62.0%  
Earnings per share (Unadj.) Rs-5.5-0.4 1,292.7%  
Cash flow per share (Unadj.) Rs0.55.6 9.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs-128.438.3 -335.2%  
Shares outstanding (eoy) m54.168.50 637.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.10.2 21.6%   
Avg P/E ratio x-0.6-59.5 1.0%  
P/CF ratio (eoy) x6.44.5 142.1%  
Price / Book Value ratio x00.7 -4.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m184216 85.5%   
No. of employees `000NANA-   
Total wages/salary Rs m512137 374.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,561901 395.4%  
Other income Rs m1522 7,248.1%   
Total revenues Rs m3,713903 411.3%   
Gross profit Rs m40299 403.8%  
Depreciation Rs m32752 633.8%   
Interest Rs m52251 1,026.9%   
Profit before tax Rs m-295-1 35,110.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m33 115.8%   
Profit after tax Rs m-298-4 8,236.5%  
Gross profit margin %11.311.0 102.1%  
Effective tax rate %-1.1-331.8 0.3%   
Net profit margin %-8.4-0.4 2,080.8%  
BALANCE SHEET DATA
Current assets Rs m2,652392 675.8%   
Current liabilities Rs m7,062544 1,298.7%   
Net working cap to sales %-123.9-16.8 737.0%  
Current ratio x0.40.7 52.0%  
Inventory Days Days15310 1,546.0%  
Debtors Days Days1,10767,725 1.6%  
Net fixed assets Rs m4,064670 606.4%   
Share capital Rs m10885 127.4%   
"Free" reserves Rs m-7,060240 -2,936.9%   
Net worth Rs m-6,952325 -2,136.1%   
Long term debt Rs m6,442140 4,609.1%   
Total assets Rs m6,7161,063 632.0%  
Interest coverage x0.41.0 44.2%   
Debt to equity ratio x-0.90.4 -215.8%  
Sales to assets ratio x0.50.8 62.6%   
Return on assets %3.34.4 75.0%  
Return on equity %4.3-1.1 -385.1%  
Return on capital %-44.510.7 -414.1%  
Exports to sales %74.21.8 4,179.3%   
Imports to sales %5.00-   
Exports (fob) Rs m2,64316 16,527.5%   
Imports (cif) Rs m176NA-   
Fx inflow Rs m2,68216 16,771.2%   
Fx outflow Rs m2600-   
Net fx Rs m2,42216 15,145.9%   
CASH FLOW
From Operations Rs m77263 1,224.3%  
From Investments Rs m-167-66 254.6%  
From Financial Activity Rs m-4831 -94,702.0%  
Net Cashflow Rs m122-2 -5,967.3%  

Share Holding

Indian Promoters % 55.6 62.6 88.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 44.5 37.4 118.8%  
Shareholders   13,596 2,259 601.9%  
Pledged promoter(s) holding % 73.5 14.7 500.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IND. SWIFT With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Indian Indices End Flat Amid High Volatility; Maruti Suzuki & Tech Mahindra Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

4 'Digital India' Stocks to Add to Your 2022 Watchlist(Views On News)

Jan 28, 2022

Digitisation is touching every aspect of our lives. As this megatrend picks up pace, there will be companies benefitting from it for years to come.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here...(Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IND. SWIFT SHARE PRICE


Jan 28, 2022 (Close)

TRACK IND. SWIFT

  • Track your investment in IND. SWIFT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IND. SWIFT 8-QTR ANALYSIS

COMPARE IND. SWIFT WITH

MARKET STATS